Linked Life Data

16449248

Source:http://linkedlifedata.com/resource/pubmed/id/16449248

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2006-3-29
pubmed:abstractText
The addition of drug elution to coronary stents plays an integral role in coronary restenosis prevention. The present study was undertaken to determine the mechanism of action and the in vitro and in vivo efficacy of zotarolimus, a new chemical entity designed specifically for elution from phosphorylcholine (PC)-coated stents, for the reduction of neointimal hyperplasia in porcine coronary arteries.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0195-668X
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
988-93
pubmed:dateRevised
2008-6-5
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks.
pubmed:affiliation
Minneapolis Heart Institute and Foundation, Minneapolis Heart Institute, 920 E. 28th St., Suite 620, Minneapolis, MN 55407, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't